• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Tesaro, Inc. (TSRO)

    50.54 Up 2.83(5.93%) Nov 25, 4:00PM EST
    ProfileGet Profile for:
    Tesaro, Inc.
    1000 Winter Street
    Suite 3300
    Waltham, MA 02451
    United States - Map
    Phone: 339-970-0900
    Website: http://www.tesarobio.com

    Index Membership:N/A
    Full Time Employees:275

    Business Summary 

    TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which has completed phase 3 oral formulation trials, as well as is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA, a programmed cell death protein 1 antibody for the treatment of certain melanomas. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Tesaro, Inc.

    Corporate Governance 
    Tesaro, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Leon O. Moulder Jr., M.B.A., 58
    Co-Founder, Chief Exec. Officer and Director
    Dr. Mary Lynne Hedley Ph.D., 52
    Co-Founder, Pres, Chief Operating Officer and Director
    Mr. Timothy R. Pearson , 47
    Chief Financial Officer and Exec. VP
    Mr. Edward C. English , 48
    Principal Accounting Officer, VP and Controller
    Mr. Jeffrey Hanke Ph.D.,
    Chief Scientific Officer and Exec. VP of R&D
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders